With a plan for 60 subjects to be completed in the current study it is unlikely that a positive outcome with statistical significance greater than p=.05 will be achieved. Thus it will be a repeat of the Rett trial requiring yet again another longer term, bigger dose, larger number study to reach criteria necessary for approval. No wonder there is such a low uptake into this study from those who recognise the pitfalls and limitations of study design. One has to ask what Larry Glass is hoping to achieve beyond a possible proof of concept from a short term low cost trial, other than further interest and non dilutional funding from big pharma. Let's do it properly first time!
- Forums
- Charts
- Fragile X study
With a plan for 60 subjects to be completed in the current study...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.80 |
Change
0.300(1.54%) |
Mkt cap ! $2.528B |
Open | High | Low | Value | Volume |
$19.49 | $19.92 | $19.25 | $5.352M | 271.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $19.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.80 | 516 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 19.780 |
2 | 1143 | 19.750 |
1 | 1441 | 19.740 |
1 | 5505 | 19.720 |
3 | 3263 | 19.700 |
Price($) | Vol. | No. |
---|---|---|
19.820 | 1081 | 2 |
19.890 | 150 | 1 |
19.900 | 2000 | 1 |
19.940 | 1143 | 2 |
19.950 | 1948 | 2 |
Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
Last
$19.80 |
  |
Change
0.300 ( 0.98 %) |
|||
Open | High | Low | Volume | ||
$19.41 | $19.92 | $19.25 | 77870 | ||
Last updated 15.59pm 17/06/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online